Increasing the antitumor effect of an EpCAM-targeting fusion toxin by facile click PEGylation by Simon, Manuel et al.
Zurich Open Repository and
Archive
University of Zurich
Main Library
Strickhofstrasse 39
CH-8057 Zurich
www.zora.uzh.ch
Year: 2014
Increasing the antitumor effect of an EpCAM-targeting fusion toxin by facile
click PEGylation
Simon, Manuel; Stefan, Nikolas; Borsig, Lubor; Plückthun, Andreas; Zangemeister-Wittke, Uwe
Abstract: Fusion toxins used for cancer-related therapy have demonstrated short circulation half-lives,
which impairs tumor localization and, hence, efficacy. Here, we demonstrate that the pharmacokinetics
of a fusion toxin composed of a designed ankyrin repeat protein (DARPin) and domain I-truncated
Pseudomonas Exotoxin A (PE40/ETA￿) can be significantly improved by facile bioorthogonal conjugation
with a polyethylene glycol (PEG) polymer at a unique position. Fusion of the anti-EpCAM DARPin
Ec1 to ETA￿ and expression in methionine-auxotrophic E. coli enabled introduction of the nonnatural
amino acid azidohomoalanine (Aha) at position 1 for strain-promoted click PEGylation. PEGylated
Ec1-ETA￿ was characterized by detailed biochemical analysis, and its potential for tumor targeting was
assessed using carcinoma cell lines of various histotypes in vitro, and subcutaneous and orthotopic tumor
xenografts in vivo. The mild click reaction resulted in a well-defined mono-PEGylated product, which
could be readily purified to homogeneity. Despite an increased hydrodynamic radius resulting from
the polymer, the fusion toxin demonstrated high EpCAM-binding activity and retained cytotoxicity
in the femtomolar range. Pharmacologic analysis in mice unveiled an almost 6-fold increase in the
elimination half-life (14 vs. 82 minutes) and a more than 7-fold increase in the area under the curve
(AUC) compared with non-PEGylated Ec1-ETA￿, which directly translated in increased and longer-
lasting effects on established tumor xenografts. Our data underline the great potential of combining the
inherent advantages of the DARPin format with bioorthogonal click chemistry to overcome the limitations
of engineering fusion toxins with enhanced efficacy for cancer-related therapy.
DOI: 10.1158/1535-7163.MCT-13-0523
Posted at the Zurich Open Repository and Archive, University of Zurich
ZORA URL: http://doi.org/10.5167/uzh-96977
Accepted Version
Originally published at:
Simon, Manuel; Stefan, Nikolas; Borsig, Lubor; Plückthun, Andreas; Zangemeister-Wittke, Uwe (2014).
Increasing the antitumor effect of an EpCAM-targeting fusion toxin by facile click PEGylation. Molecular
Cancer Therapeutics, 13(2):375-385. DOI: 10.1158/1535-7163.MCT-13-0523
Increasing the anti-tumor effect of an EpCAM-targeting fusion toxin by 
facile click PEGylation 
Manuel Simon1,2, Nikolas Stefan2, Lubor Borsig3, Andreas Plückthun2 and Uwe 
Zangemeister-Wittke1,2 
 
1Institute of Pharmacology, Friedbühlstrasse 49, University of Bern, CH-3010 Bern, 
Switzerland 
2Department of Biochemistry, Winterthurerstrasse 190, University of Zurich, CH-8057 
Zurich, Switzerland 
3Institute of Physiology, Winterthurerstrasse 190, University of Zurich, CH-8057 Zurich, 
Switzerland 
Corresponding authors:  
Andreas Plückthun, Department of Biochemistry, University of Zurich, Winterthurerstrasse 
190, CH-8057 Zürich, Switzerland, E-mail: plueckthun@bioc.uzh.ch, Phone: +41-44-635-
5570, Fax: +41-44-635-5712  
or  
Uwe Zangemeister-Wittke, Department of Biochemistry, University of Zürich, 
Winterthurerstrasse 190, 8057 Zürich, Switzerland and Institute of Pharmacology, University 
of Bern, Friedbühlstrasse 49, 3010 Bern, Switzerland. E-mail: 
uwe.zangemeister@pki.unibe.ch, Phone: +41-31-632 3290, Fax: +41-31- 632 4992 
 
Running title: Click-PEGylated fusion toxin 
Key words: click PEGylation, DARPin-based fusion toxin, molecular pharmacology, novel 
drug delivery systems, tumor targeting 
 
 
on March 25, 2015. © 2013 American Association for Cancer Research. mct.aacrjournals.org Downloaded from 
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. 
Author Manuscript Published OnlineFirst on November 1, 2013; DOI: 10.1158/1535-7163.MCT-13-0523 
2 
 
Financial support 
This work was supported by Swiss National Science Foundation grants 310030_119859 and 
31003A_138201 to U. Zangemeister-Wittke and A. Plückthun. 
 
Conflict of Interest Statement 
A. Plückthun is a shareholder of Molecular Partners AG, which is commercializing the 
DARPin technology. The other authors disclosed no potential conflicts of interest. 
 
 
 
  
on March 25, 2015. © 2013 American Association for Cancer Research. mct.aacrjournals.org Downloaded from 
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. 
Author Manuscript Published OnlineFirst on November 1, 2013; DOI: 10.1158/1535-7163.MCT-13-0523 
3 
 
Abstract 
Fusion toxins used for cancer therapy have demonstrated short circulation half-lives, which 
impairs tumor localization and hence efficacy. Here, we demonstrate that the 
pharmacokinetics of a fusion toxin composed of a Designed Ankyrin Repeat Protein 
(DARPin) and domain I-truncated Pseudomonas Exotoxin A (PE40/ETA") can be 
significantly improved by facile bioorthogonal conjugation with a polyethylene glycol 
polymer at a unique position. Fusion of the anti-EpCAM DARPin Ec1 to ETA” and 
expression in methionine-auxotrophic E. coli enabled introduction of the non-natural amino 
acid azidohomoalanine at position 1 for strain-promoted click PEGylation. PEGylated Ec1-
ETA” was characterized by detailed biochemical analysis, and its potential for tumor 
targeting was assessed using carcinoma cell lines of various histotypes in vitro, and 
subcutaneous and orthotopic tumor xenografts in vivo. The mild click reaction resulted in a 
well-defined mono-PEGylated product, which could be readily purified to homogeneity. 
Despite an increased hydrodynamic radius resulting from the polymer, the fusion toxin 
demonstrated high EpCAM-binding activity and retained cytotoxicity in the femtomolar 
range. Pharmacological analysis in mice unveiled an almost 6-fold increase in the  elimination 
half-life (14 vs. 82 min) and a more than 7-fold increase in the AUC compared to non-
PEGylated Ec1-ETA”, which directly translated in increased and longer-lasting effects on 
established tumor xenografts. Our data underline the great potential of combining the inherent 
advantages of the DARPin format with bioorthogonal click chemistry to overcome the 
limitations of engineering fusion toxins with enhanced efficacy for cancer therapy. 
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Introduction 
Tumor targeting with naked antibodies and antibody drug conjugates (ADC) has become an 
established strategy for cancer therapy, particularly if conventional therapies have failed (1, 
2). Recent advances in antibody engineering and linker technology, together with a growing 
arsenal of potent anti-cancer agents, have paved the way for the development of drug 
conjugates targeting tumors with exquisite efficacy and specificity (1-3). In theory, many 
different types of payloads can be linked to antibodies, in practice, however, engineering 
ADC with high stability and efficacy has been hampered by technical limitations and 
unfavorable properties inherent to the antibody format (3-6). 
Designed Ankyrin Repeat Proteins (DARPins) are derived by consensus engineering from 
naturally occurring repeat proteins and are composed of internal repeat modules responsible 
for binding and a N- and C-terminal capping repeat providing solubility (4, 5, 7). Their robust 
nature and high expression yield in soluble form in E. coli make them ideal candidates for 
many biomedical applications (5, 8, 9). Importantly, DARPins lack cysteines, which can thus 
be introduced for site-specific conjugation of effector functions. Recently, we reported the use 
of bioorthogonal click chemistry as a further strategy of DARPin functionalization (8, 9). The 
DARPin scaffold was found to well tolerate the replacement of its N-terminal methionine by a 
non-natural clickable L-azidohomoalanine (and, if necessary, by mutating any other Met 
residues), resulting in a fully functional binder, which can be site-specifically conjugated with 
polyethylene glycol (PEG) or other conjugation partners in a one-step reaction (8, 9). 
We previously generated high-affinity DARPins targeting various tumor-associated antigens, 
including members of the EGFR family (10, 11) and the epithelial cell adhesion molecule 
(EpCAM) (12). EpCAM, also known as CD326, is a 40 kDa type I membrane glycoprotein 
involved in cell proliferation by linking to components of the Wnt signaling pathway and 
regulators of the cell cycle (13, 14). It initially attracted attention as a target for cancer 
immunotherapy due to its abundant expression in solid tumors, whilst expression in normal 
epithelia is low (13-16), and recent studies further unveiled its association with cancer stem 
cells (14-18) and circulating tumor cells (15, 17, 18). Currently, several anti-EpCAM 
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antibodies are under clinical development (15) with the human antibody adecatumumab being 
the most advanced candidate (19, 20).  
In addition to immunotherapy with naked antibodies, EpCAM has been successfully 
evaluated also for tumor targeting with drug conjugates owing to its high rate of receptor-
mediated endocytosis (21-25). Domain I-truncated variants of Pseudomonas Exotoxin A 
(PE40/PE38) have been most frequently used for this purpose in the form of recombinant 
fusion toxins with antibody fragments or cytokines (26, 27). Although so far clinical 
responses have been limited to hematologic malignancies (28), there is hope that recent 
advances in protein engineering may eventually provide novel fusion toxin generations with 
efficacy also against solid tumors. Recently, we demonstrated for the first time the 
compatibility of the DARPin format with PE40 (here denoted ETA”) to produce high yields 
of a potent anti-EpCAM fusion toxin (24). Since, however, these small recombinant proteins 
have an elimination half-life of hardly more than 10 min (24, 29, 30), which limits tumor 
localization, pharmacological improvements are mandatory. PEGylation offers several 
advantages to biomedical compounds including an increased hydrodynamic radius and serum 
stability, resulting in increased blood residence time due to decreased proteolysis, renal 
filtration and liver clearance, and delayed recognition by the immune system (31, 32). So far, 
nine PEGylated protein products have been marketed which could demonstrate improved 
efficacy for various diseases (33). 
To increase the circulation half-life of the anti-EpCAM fusion toxin Ec1-ETA", we used 
strain-promoted click chemistry for bioorthogonal PEGylation upon introduction of a unique 
azidohomoalanine at the N-terminus of DARPin Ec1. The new generation fusion toxin 
retained EpCAM-binding affinity in the pM range and demonstrated enhanced anti-tumor 
efficacy in vivo as a result of its improved pharmacokinetic performance.  
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Materials and Methods 
All chemicals were purchased from Sigma-Aldrich (Buchs, Switzerland). E. coli strain 
B834(DE3) (F- ompT gal hsdSB (rB- mB-) met dcm lon (lacI, lacUV5-T7 gene 1, ind1, sam7, 
nin5)) was from EMD Chemicals Inc. (Gibbstown, New Jersey, U.S.A.). aza-
dibenzocyclooctyne-polyethylene glycol (20 kDa) (DBCO-PEG20kDa) was a kind gift of Click 
Chemistry Tools (Scottsdale, Arizona, U.S.A.). 
 
Tumor cell lines 
All cell lines were obtained from and authenticated by ATCC (American Type Culture 
Collection, Manassas, Virginia U.S.A.). The EpCAM-positive breast carcinoma cell lines 
MDA-MB-468 (HTB-132) and MCF7 (HTB-22) were purchased in 2011 and 2008, 
respectively. The EpCAM-positive colorectal carcinoma cell line HT29 (HTB-38) and the 
EpCAM-negative non-Hodgkin's lymphoma cell line RL (CRL-2261) were both purchased in 
2006. Cells were cultured in humidified incubators (37°C, 5% CO2) in DMEM or RPMI 1640 
(Invitrogen Inc., Basel, Switzerland) medium supplemented with 10% fetal calf serum 
(Amimed, Basel, Switzerland) and 1% penicillin/ streptavidin (Invitrogen). All cells were 
tested negative for mycoplasma. 
 
Site-directed mutagenesis of DARPins 
All internal ATG codons of control DARPin Off7 (binding to maltose binding protein) were 
exchanged to alanine codons using site-directed mutagenesis. The mutation M34L was first 
introduced as described (8, 9) before the primers 5’-
CGCTGCGGACTCTGATGGTGCGACTCCACTGCACCTGGC-3’ and 5’-
GTCGCACCATCAGAGTCCGCAGCGTTAACGTCAGCACCG-3’ were used to remove all 
internal ATG codons from the DARPin sequence. The resulting DARPin was sequenced and 
designated Off7∆M. The anti-EpCAM DARPin Ec1 (12) has no internal methionine codons. 
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Expression and purification of Aha-modified fusion toxins 
The DARPins Ec1 and Off7ΔM were subcloned into pQIq vectors using BamHI and HindIII, 
for fusion to ETA” via a Gly-Ser linker (24). All constructs were sequenced and the 
methionine-auxotrophic E. coli B-strain B834(DE3) was transformed. A single colony was 
taken to inoculate 2×YT medium supplemented with 1% glucose and 100 µg/ml ampicillin 
and grown overnight. Both Aha-Ec1-ETA” and Aha-Off7ΔM-ETA” were expressed using a 
modified medium exchange method to substitute Met by Aha during expression (8, 9). Met-
containing Ec1-ETA” was expressed from the same plasmid, pQIq-Ec1-ETA”, using E. coli 
BL21(DE3) with TB medium and purified via IMAC as described (24). For endotoxin 
removal, 300 to 500 column volumes (CV) of PBS-T (PBS, pH 7.4, 0.1% Triton-X-114) were 
used during the IMAC purification procedure. All proteins were eluted in PBS_E (PBS, 
300 mM imidazole, pH 7.4) and the protein yield was determined with a Nanodrop 1000 
photometer (Thermo Scientific AG, Wohlen, Switzerland). 
 
PEGylation of fusion toxins using click chemistry 
A stock of 5 mM DBCO-PEG20kDa (Click Chemistry Tools) was used to PEGylate the azido-
modified DARPin-ETA” fusion proteins. DBCO-PEG20kDa was added in a 2-fold molar 
excess to the IMAC purified proteins in PBS_E (1×PBS, 300 mM imidazole), mixed gently 
and left for up to 24-72 h at 4 °C for bioorthogonal mono-PEGylation using Cu(I)-free click 
chemistry. PEGylation was monitored by 12% SDS PAGE prior to further purification. 
To generate a reversibly PEGylated fusion toxin as control, a 3C protease cleavage site was 
introduced between the N-terminal MRGSH6-tag and DARPin. This was encoded by insertion 
of a double-stranded oligonucleotide at a BamHI site. The protein was expressed, PEGylated 
and purified as described above. Proteolytic removal of the N-terminal PEG20kDa was 
achieved by co-incubation of 0.1 eq 3C protease with PEG20kDa-3C-DARPin-ETA” at 5 µM 
for 2 h on ice. De-PEGylation was detected by SDS PAGE. 
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Purification of fusion toxins 
The fusion toxins were diluted in buffer A (50 mM Hepes, 20 mM NaCl, pH 8.0) and loaded 
on an anion exchange column (Mono Q GL 5/50, GE Healthcare, Glattbrugg, Switzerland) 
connected to an ÄKTA Explorer FPLC (GE Healthcare) for separation of the conjugate 
PEG20kDa-Ec1-ETA” from the reactants DBCO-PEG20kDa and Aha-Ec1-ETA”. The proteins 
were separated with a step gradient of buffer B (50 mM Hepes, 1 M NaCl, pH 8.0), and the 
peak fraction corresponding to PEG20kDa-Ec1-ETA” was pooled. The peak of non-PEGylated 
protein was also pooled, concentrated (Amicon Ultra-4 Centrifugal Unit, MWCO 30 kDa) and 
the buffer was exchanged to PBS. The concentration was determined with a Nanodrop 1000 
and the non-PEGylated protein was again subjected to PEGylation using a 2-fold excess of 
DBCO-PEG20kDa, followed by separation via anion exchange as mentioned above. The 
PEGylated protein fractions were further concentrated to a small volume followed by gel 
filtration on a Superdex 200 prep grade 16/60 column (GE Healthcare) using PBS pH 7.2 as 
running buffer. The concentrations of the resulting mono-PEGylated fusion toxins were 
measured with a Nanodrop 1000, diluted, aliquoted, snap frozen and stored at -80 °C until 
use. 
All proteins were analyzed by SDS PAGE and stained with Coomassie Brilliant Blue and 
iodine to confirm PEGylation according to Kurfürst (34). Briefly, gels previously stained with 
Coomassie were incubated for 10 min in water followed by 15 min in 20 ml 0.1 M perchloric 
acid. Then, 5 ml 5% BaCl2 in 1 M HCl and 2 ml 0.05 M iodine solution was added, and the 
gels were incubated briefly until PEG staining became visible. Gels were finally destained 
with water. 
 
Analytical gel filtration 
Ec1-ETA” and PEG20kDa-Ec1-ETA” were analyzed by analytical size exclusion 
chromatography using an ÄKTA Micro FPLC device (GE Healthcare). A volume of 50 µl of 
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each protein solution (final concentration 5 µM) was separated on a Superdex 200 PC3.2/30 
column (GE Healthcare) using PBS pH 7.2 as running buffer. A standard containing β-
amylase, BSA and cytochrome c was applied in a separate run to determine the apparent 
molecular weight (Mwapp) of the fusion toxins. 
 
Surface plasmon resonance measurements 
The affinity of non-PEGylated Ec1-ETA”, N-terminally modified Aha-Ec1-ETA” (containing 
the N-terminal azidohomoalanine instead of methionine) and the PEGylated fusion toxin 
PEG20kDa-Ec1-ETA” was determined using surface plasmon resonance (SPR) measurements 
on a ProteOn XPR36 (Bio-Rad Laboratories AG, Cressier, Switzerland). For all 
measurements, a medium to high density (1000 RU) of biotinylated extracellular domain of 
EpCAM (EpEX-bio) was immobilized on a NLC chip (Bio-Rad) and thoroughly equilibrated 
with sterile-filtered running buffer (PBS, 3 mM EDTA, 0.005% Tween-20) with a flow rate 
of 60 µl/min. For association with EpCAM, different concentrations prepared in a serial 
dilution (100 nM, 31.6 nM, 10 nM, 3.16 nM, 1 nM) were applied in parallel on separate 
analyte channels and in duplicates for 417 s. Dissociation of proteins from the chip was 
monitored for 10,000 s. Data were normalized using interspot referencing and subtraction of a 
separate analyte channel run with buffer only. All sensograms were fitted using a 1:1 
Langmuir model provided by the ProteOn Manager Software (Bio-Rad), and the association 
(ka) and dissociation (kd) rate constants were used to determine the equilibrium dissociation 
constants (KD).  
 
Limulus amebocyte lysate (LAL) assay 
Contamination of the fusion toxins with endotoxin was measured using the LAL assay 
(Charles River, Sulzfeld, Germany) following the manufacturer’s protocol. 
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Cytotoxicity assay 
Serial dilutions of the fusion toxins were used to determine the IC50 (concentration at which 
cell viability was decreased by 50%) of the constructs in XTT assays (Cell Proliferation Kit 
II, Roche Diagnostics GmbH, Mannheim, Germany). Briefly, 5000 cells were seeded into a 
96-well plate, incubated overnight in a standard humidified cell culture incubator (37°C, 5 % 
CO2) and treated with the fusion toxins in quadruplicates the following day. The medium was 
discarded after 96 h, 50 µl of XTT reagent were added and cells were incubated for 1-3 h at 
37 °C. The cytotoxicity of the reversibly PEGylated fusion toxin was measured in 72 h XTT 
assays using HT29 cells in the presence of 3C protease. 
Cell viability was analyzed in an Infinite® M1000 Pro plate reader (Tecan, Männedorf, 
Switzerland) at 480 nm. Untreated cells were used for normalization. The data were analyzed 
using Excel (Microsoft, Redmond, Washington, U.S.A.) and Prism (v 5.04, GraphPad 
Software Inc., U.S.A.). If possible, logarithmic protein concentration vs. response curves were 
fitted to data points (using three parameters). 
 
In vitro serum stability of fusion toxins 
The fusion toxins Ec1-ETA” and PEG20kDa-Ec1-ETA” were diluted to a concentration of 2 
µg/ml in non-heat-inactivated mouse serum (PAA, Pasching, Austria) and incubated at 37°C 
to mimic the situation in vivo after i.v. injection. At different time points (0, 0.5, 1, 2, 3, 6 h), 
100 µl of the samples were snap-frozen and stored at -20 °C. For analysis, samples were 
thawn on ice and incubated with magnetic protein G beads (Dynabeads Protein G, Life 
Science Technologies) previously coated with rabbit anti-Pseudomonas Exotoxin polyclonal 
serum (P2318, Sigma-Aldrich, St. Louis, Missouri, U.S.A.) for 30 min. The fusion toxin was 
pulled-down from serum using a magnetic rack and washed according to the manufacturer’s 
protocol. Magnetic beads were directly mixed with non-reducing 1 × SDS loading buffer and 
proteins were eluted by boiling for 10 min. The non-purified samples were loaded directly on 
a 12% SDS PAGE gel and subjected to semi-dry Western blotting. Membranes were blocked 
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overnight with milk powder using PBS-TM (1×PBS, 0.1% Tween-20, 5% skimmed non-fat 
milk powder) and the membrane was incubated for 1 h at room temperature with a mouse 
anti-His6 IgG1 horseradish peroxidase conjugate (#11965085001, Roche Diagnostics AG, 
Rotkreuz, Switzerland) diluted 1:500 in PBS-TM. A chemiluminescent HRP substrate was 
used for detection (ImmobilonTM Western, Millipore Corporation, Billerica, U.S.A.). 
 
Blood clearance of fusion toxins 
Elimination half-life (t1/2) and area-under-the-curve (AUC) of Ec1-ETA” and PEG20kDa-Ec1-
ETA” were determined in serum from female 8-10 weeks old CD1 nude mice (Charles 
River). Groups of four mice received a single dose of 170 pmol/mouse i.v. and blood samples 
were drawn from the tail tip at various time points (3, 10, 30, 60, 120 min for Ec1-ETA” or 3, 
60, 180, 360, 720 min for PEG20kDa-Ec1-ETA”). Collected blood samples were left for 30 min 
at room temperature followed by two centrifugation steps (3,000×g, 20 min and 10,000×g, 20 
min) to allow the separation of serum. The serum samples were snap-frozen and stored at -20 
°C until use. 
The amount of Ec1-ETA” and PEG20kDa-Ec1-ETA” in serum was measured using a 
quantitative ELISA. Briefly, MaxiSorp™ 96-well plates (Nunc GmbH & Co. KG, 
Langenselbold, Germany) were coated for 1 h at room temperature with mouse anti-tetra-His 
antibody at a dilution of 1:1000 in PBS (Qiagen, Hilden, Germany) or with BSA for 
normalization. The wells were blocked overnight at 4°C with PBS-B (PBS, 0.2 % BSA). For 
detection of fusion toxins in serum, a dilution of 1:100 or 1:300 of the samples was applied in 
duplicates on the pre-coated plate. A serial dilution of both Ec1-ETA” and PEG20kDa-Ec1-
ETA” was included on each plate as standard for quantification. All samples were incubated 
for 1 h at room temperature followed by stringent washes with PBS-T (PBS, 0.1% Tween-
20). A dilution of 1:5000 of rabbit anti-PE polyclonal serum (Sigma) was added as primary 
antibody (1 h at room temperature) in PBS-TB (PBS, 0.2 % BSA, 0.1 % Tween-20) followed 
by washing with PBS-T and incubation with goat-anti-rabbit IgG-HRP conjugate (Sigma) 
diluted 1:10,000 in PBS-TB for 1 h at room temperature. The plates were washed with PBS-T 
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and the fusion toxins were assayed using the Amplex® Red ELISA detection kit (Invitrogen, 
Life Technologies Europe B.V., Zug, Switzerland). All wells were normalized with the 
appropriate BSA control wells and protein was quantified using the standard curves for Ec1-
ETA” or PEG20kDa-Ec1-ETA”.  
The measured concentrations were plotted using GraphPad Prism Software and curves were 
fitted with a mono-exponential decay function. Prism was used to determine the serum half-
life of the fusion toxins and the corresponding AUC. Furthermore, data were used to calculate 
the clearance (CL), excretion constant rate (ke) and volume of distribution (VD). 
 
Examination of anti-tumor effects 
Subcutaneous (s.c.) tumor xenografts were raised by injection of 1×107 EpCAM-positive 
HT29 cells in a volume of 100 µl in the right lateral flank of 6-8 week old female CD1 nude 
mice (Charles River, Hannover, Germany). Tumors were measured with calipers and the 
volume was calculated with the formula (short2 × long diameter) × 0.4. After 5-7 days when 
tumors reached an average size of 50-60 mm3, mice were randomized to groups of 5 per 
cohort and treatment was started the following day (day 0) by i.v. injection of 340 pmol (equal 
to 20 µg protein) Ec1-ETA”, PEG20kDa-Ec1-ETA”, PEG20kDa-Off7ΔM-ETA” or PBS in a 
volume of 100 µl. The treatment was repeated on day 4, 8 and 12, and mice were monitored 
for 28 days. 
To raise orthotopic tumors, 1×107 EpCAM-positive MDA-MB-468 cells in a volume of 100 
µl were mixed on ice 1:1 with matrigel (Becton Dickinson AG, Allschwill, Switzerland) and 
100 µl of the mixture (5×106 cells) were injected into the mammary fat pad of 6–8 week old 
female CD1 nude mice. Tumor growth was measured as described above. After 6 weeks, 
when tumors had reached an average size of ~50 mm3, mice were randomized in groups of 5-
7 per cohort and treatment was started the following day (day 0) by i.v. injection of 340 pmol 
(equal to 20 µg protein) Ec1-ETA”, PEG20kDa-Ec1-ETA”, PEG20kDa-Off7ΔM-ETA” or PBS in 
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a volume of 100 µl. The treatment was repeated on day 4, 8 and 12 and 16, and mice were 
monitored for 40 days. 
 
Statistical analysis 
All data are presented as mean ± SD or SEM. The in vitro serum-stability of the various 
fusion toxin preparations was compared using a paired t-test. The differences in tumor growth 
were analyzed using the Kruskal-Wallis test. As post test, Dunn’s multiple comparison test 
was used to compare PEG20kDa-Ec1-ETA” and Ec1-ETA”. P < 0.05 was considered 
statistically significant. 
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Results 
Generation of fusion toxins containing a unique azidohomoalanine 
To enable site-specific modification using click chemistry, the anti-EpCAM DARPin Ec1 was 
subcloned into the respective vector as described (24) to generate a fusion toxin with domain 
I-truncated Exotoxin A (PE40, here denoted ETA”) (Fig. 1A). In parallel, internal Met codons 
were removed from the non-targeted control DARPin Off7 by two-step site-directed 
mutagenesis, and then fused to ETA”. 
The DARPin-ETA” fusion toxins were expressed in the methionine-auxotrophic E. coli strain 
B834(DE3), followed by a medium exchange strategy for metabolic introduction of the non-
natural amino acid azidohomoalanine (Aha) at the N-terminus (8, 9). Purification was done by 
IMAC, including extensive washing with Triton-X114 to remove endotoxins. The proteins 
were analyzed by SDS PAGE and showed the expected molecular weight of 58.7 kDa (Fig. 
1B). This resulted in purified soluble Aha-containing fusion toxins at yields up to 4 mg/l in 
shake flasks. 
 
Bioorthogonal PEGylation of fusion toxins using click chemistry 
For subsequent PEGylation at the N-terminus, the fusion toxins were mixed with a two-fold 
excess of DBCO-PEG20kDa in PBS at 4 °C. As described previously (8), PEG reacted in a 
time-dependent manner, leading to exclusively mono-PEGylated protein as detected by a 
single band-shift towards higher molecular weight (about 90-100 kDa) by SDS PAGE (Fig. 
1B). The PEGylated proteins were separated from unconjugated PEG by anion exchange 
chromatography (Supplementary Fig. S1A, S1B). Subjection of the non-reacted fraction to a 
second round of PEGylation with a two-fold excess of DBCO-PEG20kDa again provided 
PEGylated products, indicating that the reactivity of the N-terminal azide of 
azidohomoalanine was retained (Supplementary Fig. S2). The pooled fractions of PEGylated 
protein were further purified using preparative gel filtration (Supplementary Fig. S1C, S1D), 
and the final products were analyzed by SDS PAGE using Coomassie and iodine staining of 
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PEG (Supplementary Fig. S1E). As shown in Figure 2, this yielded exclusively mono-
PEGylated protein without side products. Analysis of endotoxin contamination in the LAL 
assay showed only trace amounts of LPS (Ec1-ETA” 3.5 EU/mg, PEG20kDa-Ec1-ETA” 1.3 
EU/mg, PEG20kDa-Off7ΔM-ETA” 13.2 EU/mg). 
In addition, we determined the increase in the hydrodynamic radii of the fusion toxins as a 
result of PEGylation by analytical gel filtration. As shown in Supplementary Figure S3, non-
PEGylated Ec1-ETA” eluted with the expected molecular weight of approximately 60 kDa, 
whereas mono-PEGylated Ec1-ETA” eluted at smaller volumes, which is comparable to a 
molecular weight of > 250 kDa typical for a mono-PEGylated protein (35). 
 
Effect of PEGylation on fusion toxin binding to EpCAM 
The binding activity of PEGylated and non-PEGylated fusion toxin was compared using SPR. 
To monitor potential intermolecular inhibition effects that might be derived from N-terminal 
PEGylation (9, 36), we immobilized EpCAM on the chip with medium to high density, 
thereby mimicking the membrane surface of EpCAM-positive target cells with high antigen 
density. Ec1-ETA” and Aha-Ec1-ETA” (which differ only in the first amino acid, by 
containing Met or Aha, respectively) showed very similar data for ka or kd (Supplementary 
Fig. S4, Supplementary Table S1). After PEGylation, however, the association rate constant 
of PEG20kDa-Ec1-ETA” was 2-fold lower compared to the non-PEGylated fusion toxin, 
whereas no difference was found for kd. This resulted in an overall reduction in KD by a factor 
of two, possibly due to intramolecular blocking effects (36) (139 pM prior to and 290 pM 
after PEGylation). In addition, the maximal response on the chip (which is proportional to the 
number of fusion toxin molecules able to interact with the surface) showed a reduction for the 
PEGylated fusion toxin, compared to its non-PEGylated counterpart, probably due to 
intermolecular blocking effects resulting from steric hindrance by the PEG20kDa polymer (36) 
(Supplementary Fig. S4, Supplementary Table S1). 
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Cytotoxicity of fusion toxins  
Tumor cell lines of different histotypes were used to determine the cytotoxicity of PEGylated 
and non-PEGylated Ec1-ETA” and the respective non-targeted control fusion toxins Off7ΔM-
ETA” and PEG20kDa-Off7ΔM-ETA”. Figure 2 shows the cell viability curves determined in 
XTT assays, the IC50 values (concentrations at which cell viability was decreased by 50%) are 
depicted in Table 1. With all EpCAM-positive cell lines, Ec1-ETA” and PEG20kDa-Ec1-ETA” 
showed IC50 values in the femtomolar range, which was up to 104-fold more potent than the 
non-targeted control fusion toxins (Fig. 2A-C). Depending on the cell line, PEG20kDa-Ec1-
ETA” was 4 to 10-fold less potent than the non-PEGylated variant (Supplementary Table S2). 
Decreased cytotoxicity upon PEGylation, however to a smaller extent and at much higher 
absolute concentrations, was also observed for the control fusion toxin Off7ΔM-ETA” (Fig. 
2). On EpCAM-negative RL cells, the potency was 4 orders of magnitude lower, indicating 
the strong EpCAM-specificity of the effect (Fig. 2D). 
We compared both the Aha and Met containing version of non-PEGylated Ec1-ETA” to 
exclude the possibility that the results were affected by using different E. coli strains for 
expression (B834(DE3)) vs. BL21(DE3)), different expression media (M9 vs. 2×YT) and/or 
different expression temperatures (30°C vs. 37°C). Both fusion toxin variants were found to 
be equally potent in XTT assays, indicating that exchanging Met by Aha did not affect 
cytotoxicity and that the reduced effect of the PEGylated variant indeed resulted from 
polymer conjugation (data not shown). 
To analyze this phenomenon further, we generated a reversibly PEGylated variant of Ec1-
ETA” from which the PEG tail can be removed. To this end, a 3C protease site was 
genetically introduced at the N-terminus between the His-tag and the DARPin to generate 
PEG20kDa-3C-Ec1-ETA” (Supplementary Fig. S5A). The protein was expressed, PEGylated, 
purified as described above and analyzed by SDS PAGE (Supplementary Fig. S5B). Cleavage 
of PEG20kDa-3C-Ec1-ETA” with 3C protease was quantitative under the conditions described 
and yielded a product with a lower molecular weight, as expected for non-PEGylated Ec1-
ETA” (Supplementary Fig. S5B). The cytotoxicity of fusion toxins was determined in XTT 
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assays with and without N-terminal PEG cleavage. As shown in Supplementary Figure S5C, 
on HT29 cells PEG20kDa-3C-Ec1-ETA” showed a 10-fold lower potency (calculated as IC50), 
compared to Ec1-ETA”, but completely regained its activity upon removal of the polymer. 
 
Serum stability and in vivo blood clearance of fusion toxins  
We first compared the serum stability of Ec1-ETA” and PEG20kDa-Ec1-ETA”, as PEGylation 
was previously shown to increase the resistance of proteins to proteolytic degradation (37). 
Interestingly, Ec1-ETA” and the PEGylated variant were found to be similarly stable in serum 
at physiological conditions and showed no signs of degradation or loss of integrity as 
analyzed by Western blotting (Supplementary Fig. S6). 
Serum levels of PEG20kDa-Ec1-ETA” and the non-PEGylated Ec1-ETA” control were 
determined by ELISA using blood samples from mice drawn at different time points after a 
single tail vein injection. Figure 3 illustrates the serum concentration profiles, the 
pharmacokinetic parameters calculated from the data by noncompartmental analysis are 
summarized in Table 2. The non-PEGylated fusion toxin was rapidly cleared from the blood, 
resulting in a terminal half-life (t1/2) of only 14 min. In contrast, mono-PEGylation decreased 
the blood clearance 6-fold and increased the half-life to 82 min. Correspondingly, the area-
under-the-curve (AUC) significantly increased 7.5-fold from 29 nM·h to 217 nM·h. 
Interestingly, the apparent volume of distribution (Vd) was similar for both fusion toxin 
variants, indicating that tissue distribution was not further reduced by the hydrophilic 
PEG20kDa polymer. The increased elimination half-life of the mono-PEGylated fusion toxin 
correlated well with a 5-fold slower clearance (Cl) (Table 2), which was likely due to reduced 
renal excretion of PEG20kDa-Ec1-ETA” with an apparent molecular weight of approx. 250 
kDa.    
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Anti-tumor effects of fusion toxins 
To assess the effect of PEGylation and half-life extension on the therapeutic efficacy of the 
non-PEGylated and PEGylated Ec1-ETA” fusion toxins, anti-tumor effects were compared in 
models of subcutaneous (s.c.) HT29 and orthotopic MDA-MB-468 tumor xenografts in nude 
mice. 
In the s.c. model, mice bearing established HT29 tumors were treated i.v. with 4 doses of 340 
pmol Ec1-ETA” or PEG20kDa-Ec1-ETA”. To minimize the non-specific systemic toxicity of 
ETA”, we chose a 4-day treatment interval. As shown in Figure 4A, tumors of mice treated 
with PEGylated and non-PEGylated Ec1-ETA” responded immediately, resulting in a steady 
decrease in tumor volume during the course of the treatment (until day 14). However, whereas 
tumors of mice treated with non-PEGylated Ec1-ETA” started to regrow to a mean size of 
161 mm3 on day 28, treatment with PEG20kDa-Ec1-ETA” resulted in a more pronounced and 
longer-lasting anti-tumor effect (p < 0.05) with longer injection-free intervals. The mean 
tumor volume measured on day 28 was only 65 mm3 and in one mouse remained stable even 
after discontinuation of the treatment. In contrast, tumors of mice treated with PBS or the 
non-targeted PEG20kDa-Off7ΔM-ETA” rapidly progressed to a mean size of 660 mm3 and 464 
mm3, respectively, on day 28 (Fig. 4A). The lack of anti-tumor activity of the non-targeted 
fusion toxin suggests that significant passive tumor localization by the enhanced permeability 
and retention (EPR) effect (31, 38) can be excluded. All treatments were well tolerated by the 
animals with only very marginal weight loss (Fig. 4B). In Figure 4C, the sizes of excised 
tumors are shown for comparison. Repetitive treatment of regrowing HT29 tumors with the 
anti-EpCAM fusion toxins on day 28, 32, and 36 unveiled that they were still responsive (data 
not shown). 
In the orthotopic tumor model, nude mice bearing established MDA-MB-468 tumors in the 
mammary fat pad were treated i.v. with 5 doses of 340 pmol Ec1-ETA” or PEG20kDa-Ec1-
ETA”. As shown in Figure 4D, compared to the PBS control, treatment with non-PEGylated 
Ec1-ETA” resulted in a transient tumor growth inhibition without decreasing the tumor size 
(82 mm3 on day 42). In contrast, tumors of mice treated with PEG20kDa-Ec1-ETA” responded 
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more strongly, resulting in significant shrinkage to an average size of 31 mm3 on day 40 with 
one animal showing complete tumor regression (p > 0.05). Again, as demonstrated for s.c. 
HT29 tumors, the control fusion toxin PEG20kDa-Off7 ΔM-ETA” had no effect on the growth 
of orthotopic MDA-MB-468 tumors (Fig. 4D). Similar to the s.c. tumor model treatments 
were well tolerated by the animals (Fig. 4E). 
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Discussion 
EpCAM is abundantly expressed in solid tumors and its rapid internalization upon ligand 
binding makes it ideal for tumor targeting with antibodies or alternative binding proteins 
payloaded with anti-cancer agents acting on intracellular targets (21, 22, 25). We previously 
reported on a fusion toxin composed of the high affinity anti-EpCAM DARPin Ec4 and 
domain I-truncated ETA (ETA", also known as PE40), which could be expressed at very high 
yields and demonstrated promising anti-tumor effects (24). Fusion toxins of this rather small 
size, however, have very short elimination half-lives of hardly more than 10 min, which 
negatively affects tumor targeting (6). To increase the therapeutic index, the half-life must be 
extended without increasing systemic toxicity. Here we improved the pharmacokinetic and 
therapeutic performance of Ec1-ETA” by bioorthogonal conjugation to a 20 kDa PEG at a 
desired position in the protein backbone.  
Conjugation of proteins to PEG is an established strategy which has been used for various 
marketed protein therapeutics and other types of medicines (39, 40). Conventional 
PEGylation procedures for proteins have used polymers activated by amine-reactive 
succinimidyl esters or thiol-reactive maleimides. However, lysines with their primary amines 
and cysteines are commonly present in proteins, which results in an unwanted mixture of 
mono- and multi-PEGylated positional isomers with random conjugation sites (39-41). To 
avoid heterogeneity of the PEGylated product, a single cysteine was introduced in the linker 
sequence of the fusion toxin for subsequent conjugation to maleimide-activated PEG (30). 
Unfortunately, this strategy may impair protein folding due to incorrect disulfide formation in 
ETA" (26, 27, 30), and stability due to possible maleimide exchange with cysteine-rich serum 
proteins (42). In a different approach, which is likely not tolerated by many proteins, Onda et 
al. (43) engineered a Lys-free immunotoxin in which a unique Lys was then introduced for 
site-specific conjugation.  
DARPins contain no cysteines and most importantly only a single N-terminal methionine at 
position 1 (ATG) in addition to another Met in the backbone, which can be conveniently 
replaced by leucine without loss of biophysical performance (8, 9). The anti-EpCAM DARPin 
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Ec1 contains even only the methionine at position 1, which we replaced by azidohomoalanine 
to enable bioorthogonal strain-promoted cycloaddition of a DBCO-activated PEG20kDa (12). 
We demonstrate that this strategy is perfectly suited to modify DARPin-ETA” fusion toxins 
beyond the classical way of protein engineering by genetic alterations. PEGylation of Ec1-
ETA" was accomplished by simply mixing the protein with DBCO-PEG20kDa, which provides 
a strained alkyne for covalent conjugation exclusively with the N-terminal azide of the fusion 
toxin. Maximum PEGylation was obtained with a low molar excess (2 eq.) of DBCO-
PEG20kDa over protein and yielded > 60% of biologically active PEG20kDa-Ec1-ETA”, which 
could be conveniently purified by anion exchange chromatography. The PEGylation yield 
was not, 100% even in the presence of a high molar excess of DBCO-PEG20kDa, however, the 
remaining unreacted protein fraction could be readily recycled from the column and 
successfully subjected to a second conjugation round, indicating that the N-terminal azide was 
still reactive. To our knowledge, PEG20kDa-Ec1-ETA” is the first protein therapeutic 
engineered for tumor targeting by click chemistry. Beyond PEGylation, the azide-directed 
conjugation of DARPins or DARPin fusion proteins described here is generic in nature and in 
principle applicable to various other conjugation partners designed to improve tumor targeting 
(44, 45).  
Even if the bulky PEG polymer is conjugated to sites remote from the active center, some loss 
of activity is commonly observed with therapeutic proteins (31). We found that PEGylation of 
Ec1-ETA” decreased its cytotoxicity 4 to 10-fold. Although the on-rate decreased 2-fold after 
PEGylation, the loss in potency cannot be simply explained by the reduced binding affinity as 
the fusion toxin was permanently present in the assays. It is, however, plausible that steric 
hindrance by the polymer decreased the absolute quantity of fusion toxin capable of 
associating with EpCAM on the cell surface (a phenomenon previously described as 
intermolecular blocking (9, 36)) as a first and crucial step of the cellular intoxication process 
of ETA”. This conclusion is supported by SPR experiments and previous binding studies with 
PEGylated Ec1 (9). Recently, from studies with the plant toxin gelonin, Pirie et al. (46) 
reported the existence of a near universal threshold for the amount of internalized toxin which 
is required for induction of cell death. It is thus conceivable that cell death induction by 
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PEG20kDa-Ec1-ETA” obeys the same rules and internalization is significantly more effective 
after unveiling of PEG once the fusion toxin is localized in the tumor. 
In contrast, to non-PEGylated Ec1-ETA", which at the tested dose schedule only inhibited 
tumor growth, PEG20kDa-Ec1-ETA” induced tumor shrinkage with one long-lasting response 
and one complete regression. This suggests that the shortcomings of PEGylation measured in 
vitro could be fully offset in vivo by half-life extension. Although the remaining tumors 
resumed growth after discontinuation of treatment, they were still responsive to a second 
treatment cycle, indicating that engineering the fusion toxin for further enhanced 
pharmacological performance is warranted. Since non-targeted PEG20kDa-Off7ΔM-ETA" did 
not affect tumor growth, a role of passive tumor targeting by the EPR effect (38) as described 
for other PEGylated nanomedicines (37, 39, 47, 48) can be excluded.  
Cellular intoxication by ETA” is a complex process (26, 49, 50), several steps of which might 
be negatively affected by a bulky polymer. Based on this consideration, PEGylation may 
improve tumor localization of the fusion toxin and reduce its uptake by the RES, but once it 
encounters its target cell becomes dispensable or even unwanted. Therefore, a construct 
engineered for de-PEGylation under specific conditions in the tumor microenvironment, e.g. 
by tumor proteases, might be advantageous. That such a design is in principle possible is 
suggested by control experiments with a reversibly PEGylated Ec1-ETA" construct for which 
cell binding and cytotoxic potency could be entirely restored after proteolytic de-PEGylation. 
In conclusion, we describe a novel anti-EpCAM fusion toxin for tumor targeting engineered 
by PEGylation using bioorthogonal click chemistry, and report its improved pharmacokinetic 
and therapeutic performance. In addition to standard protein engineering techniques, the high 
compatibility of DARPins and drug conjugates derived thereof with click chemistry opens 
new perspectives for more effective cancer therapy. 
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Table 1. Cytotoxicity of fusion toxins against various tumor cell lines.  
 
Cell line Ec1-ETA” 
 
(mol/l) 
PEG20kDa- 
Ec1-ETA” 
(mol/l) 
Off7ΔM-ETA” 
 
(mol/l) 
PEG20kDa- 
Off7ΔM-ETA” 
(mol/l) 
HT29 5.1 × 10-14 5.1 × 10-13 1.3 × 10-9 6.8 × 10-10 
MDA-MB-468 4.2 × 10-13 3.4 × 10-12 2.4 × 10-9 5.4 × 10-9 
MCF7 5.9 × 10-14 2.5 × 10-13 2.1 × 10-10 4.0 × 10-10 
RL > 1 × 10-8 > 1 × 10-8 > 1 × 10-8 > 1 × 10-8 
 
Data represent IC50 values calculated from the curves depicted in Fig. 3 after fitting by non-
linear regression. 
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Table 2. Pharmacokinetics of Ec1-ETA” and PEG20kDa-Ec1-ETA” in nude mice upon a 
single i.v. injection. 
 
 
AUC0-last 
(nM · h) 
t1/2 
(min) 
Cl 
(l · h-1 · kg-1) 
Vd 
(l · kg-1) 
kel 
(h-1) 
Ec1-ETA” 45 14.1 151.2 0.073 2.95 
PEG20kDa-Ec1-ETA” 217 81.6 31.2 0.068 0.51 
 
Data were calculated from the blood clearance curves shown in Fig. 4. AUC0-last = area-under-
the serum concentration curve; t1/2 = elimination half-life; Cl = clearance; Vd = apparent 
volume of distribution; kel = first-order elimination rate constant. 
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Figure Legends 
 
Figure 1. (A) Schematic illustration of the bioorthogonal modification of Ec1-ETA” by 
Cu(I)-free click chemistry. The non-natural amino acid azidohomoalanine is introduced 
uniquely at amino acid position 1 (or any other position in the polypeptide chain). Addition of 
DBCO-activated compounds such as PEG (shown as “R”) results in site-specific modification 
at the desired position by formation of a stable covalent triazole linkage. (B) SDS PAGE 
analysis of PEGylated fusion toxins. 5 µg of each protein was loaded on a reducing 12% gel 
and mono-PEGylation was detected as a band-shift towards higher molecular weight. 
 
Figure 2. Cytotoxicity of PEGylated and non-PEGylated fusion toxins against various tumor 
cell lines determined in 96 h XTT assays. Serial dilutions of the proteins were added to the 
EpCAM-positive cell lines (A) HT29, (B) MDA-MB-468, and (C) MCF7. (D) The EpCAM-
negative cell line RL was used as a non-target control. Bars = SD. 
 
Figure 3. Blood clearance of Ec1-ETA” and PEG20kDa-Ec1-ETA” determined in CD1 nude 
mice upon a single i.v. injection of 170 pmol protein. Serum titers were calculated from blood 
samples of 4 mice per group drawn at different time points after injection. Bars = SD 
 
Figure 4. (A) Effect of PEGylated and non-PEGylated fusion toxins on s.c. growing HT29 
tumors. 7-10 days after s.c. tumor inoculation (107 cells in 100 µl), mice were injected 4 times 
i.v. with 100 μl of a 340 pmol solution (equivalent to 20 μg protein) of either EpCAM-
targeted PEG20kDa-Ec1-ETA”, Ec1-ETA” or the non-targeted control fusion toxin PEG20kDa-
Off7ΔM-ETA”. Control mice received equal volumes of PBS. Tumor growth was monitored 
for 28 days by caliper measurements. (B) Body weight of mice during treatment with the 
fusion toxins or PBS. (C) Size of representative HT29 tumors from each treatment group. 
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Mice were euthanized on day 40 after the start of the treatment and tumors were excised for 
comparison. (D) Effect of PEGylated and non-PEGylated fusion toxins on orthotopically 
growing MDA-MB-468 tumors. 6 weeks after tumor cell inoculation into the mammary fat 
pad (5×106 cells in 100 µl), mice were injected 5 times i.v. with 100 µl of a 340 pmol solution 
of the fusion toxins, control mice received equal volumes of PBS. Tumor growth was 
monitored for 6 weeks by caliper measurements. (E) Body weight of mice during treatment 
with the fusion toxins or PBS. Arrows indicate injection time points; Bars = SEM; *, p < 0.05. 
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